Nanologica AB (publ) (NICA.ST)
SEK 0.87
(-5.83%)
SEK 0.87
(-5.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -75.15 Million SEK | -36.43% |
| 2022 | -55.09 Million SEK | -9.89% |
| 2021 | -50.13 Million SEK | -101.93% |
| 2020 | -24.82 Million SEK | -15.61% |
| 2019 | -21.47 Million SEK | -2.8% |
| 2018 | -20.88 Million SEK | -3.95% |
| 2017 | -20.09 Million SEK | 10.53% |
| 2016 | -22.45 Million SEK | -57.16% |
| 2015 | -14.29 Million SEK | 2.94% |
| 2014 | -14.72 Million SEK | -46.3% |
| 2013 | -10.06 Million SEK | -99.86% |
| 2012 | -5.03 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -16.76 Million SEK | 54.48% |
| 2024 Q2 | -11.12 Million SEK | 33.65% |
| 2023 Q1 | -13.46 Million SEK | 12.96% |
| 2023 Q3 | -11.55 Million SEK | 27.92% |
| 2023 Q2 | -16.02 Million SEK | -19.01% |
| 2023 FY | -75.15 Million SEK | -36.43% |
| 2023 Q4 | -36.83 Million SEK | -218.84% |
| 2022 Q3 | -12.36 Million SEK | 15.01% |
| 2022 Q2 | -14.54 Million SEK | 10.4% |
| 2022 FY | -55.09 Million SEK | -9.89% |
| 2022 Q1 | -16.23 Million SEK | -6.67% |
| 2022 Q4 | -15.47 Million SEK | -25.15% |
| 2021 Q1 | -7.84 Million SEK | -82.78% |
| 2021 FY | -50.13 Million SEK | -101.93% |
| 2021 Q2 | -9.21 Million SEK | -17.48% |
| 2021 Q4 | -15.22 Million SEK | -21.33% |
| 2021 Q3 | -12.54 Million SEK | -36.13% |
| 2020 Q1 | -6.18 Million SEK | 0.63% |
| 2020 FY | -24.82 Million SEK | -15.61% |
| 2020 Q4 | -4.29 Million SEK | 39.57% |
| 2020 Q2 | -4.61 Million SEK | 25.36% |
| 2020 Q3 | -7.1 Million SEK | -53.79% |
| 2019 FY | -21.47 Million SEK | -2.8% |
| 2019 Q3 | -5.17 Million SEK | -3.29% |
| 2019 Q2 | -5.01 Million SEK | -58.22% |
| 2019 Q1 | -3.16 Million SEK | 30.78% |
| 2019 Q4 | -6.22 Million SEK | -20.22% |
| 2018 Q1 | -5.27 Million SEK | -195.05% |
| 2018 Q2 | -6.16 Million SEK | -16.89% |
| 2018 Q3 | -4.88 Million SEK | 20.76% |
| 2018 Q4 | -4.57 Million SEK | 6.21% |
| 2018 FY | -20.88 Million SEK | -3.95% |
| 2017 Q2 | -6.73 Million SEK | -0.28% |
| 2017 FY | -20.09 Million SEK | 10.53% |
| 2017 Q4 | -1.78 Million SEK | 63.23% |
| 2017 Q3 | -4.85 Million SEK | 27.87% |
| 2017 Q1 | -6.71 Million SEK | -65.23% |
| 2016 Q1 | -5.62 Million SEK | -18.73% |
| 2016 FY | -22.45 Million SEK | -57.16% |
| 2016 Q4 | -4.06 Million SEK | 34.92% |
| 2016 Q3 | -6.24 Million SEK | 4.31% |
| 2016 Q2 | -6.52 Million SEK | -16.1% |
| 2015 Q4 | -4.73 Million SEK | -7.34% |
| 2015 Q1 | -1.53 Million SEK | 68.04% |
| 2015 Q2 | -3.61 Million SEK | -135.84% |
| 2015 FY | -14.29 Million SEK | 2.94% |
| 2015 Q3 | -4.41 Million SEK | -22.09% |
| 2014 Q4 | -4.79 Million SEK | 0.0% |
| 2014 Q2 | -2.56 Million SEK | 0.0% |
| 2014 Q1 | -2.56 Million SEK | 0.0% |
| 2014 FY | -14.72 Million SEK | -46.3% |
| 2014 Q3 | -4.79 Million SEK | -86.57% |
| 2013 FY | -10.06 Million SEK | -99.86% |
| 2012 FY | -5.03 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -485.882% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 75.829% |
| NextCell Pharma AB | -41.95 Million SEK | -79.117% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -358.331% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 80.638% |
| AcouSort AB (publ) | -17.08 Million SEK | -339.798% |
| OncoZenge AB (publ) | -15.9 Million SEK | -372.626% |
| Xintela AB (publ) | -54.08 Million SEK | -38.966% |
| Ziccum AB (publ) | -21.41 Million SEK | -251.004% |
| Active Biotech AB (publ) | -45.8 Million SEK | -64.098% |
| Alzinova AB (publ) | -16.48 Million SEK | -356.05% |
| Amniotics AB (publ) | -30.87 Million SEK | -143.463% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 69.766% |
| BioArctic AB (publ) | 229.24 Million SEK | 132.784% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 83.878% |
| Camurus AB (publ) | 431.44 Million SEK | 117.42% |
| Cantargia AB (publ) | -280.02 Million SEK | 73.161% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -256.346% |
| CombiGene AB (publ) | -35.66 Million SEK | -110.728% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 50.506% |
| Genovis AB (publ.) | 61.5 Million SEK | 222.207% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 33.679% |
| Mendus AB (publ) | -101.61 Million SEK | 26.04% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -102.738% |
| Kancera AB (publ) | -64.88 Million SEK | -15.824% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1495.414% |
| LIDDS AB (publ) | -40.2 Million SEK | -86.93% |
| Lipum AB (publ) | -37.17 Million SEK | -102.154% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -519.698% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 717.61% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -319.942% |
| Saniona AB (publ) | -95.81 Million SEK | 21.556% |
| Simris Alg AB (publ) | -37.3 Million SEK | -101.466% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 58.169% |
| Intervacc AB (publ) | -102.85 Million SEK | 26.927% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -17059.132% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -354.863% |
| Corline Biomedical AB | -1.8 Million SEK | -4054.616% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 57.739% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -32.27% |
| Aptahem AB (publ) | -11.11 Million SEK | -576.306% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 38.931% |
| Fluicell AB (publ) | -26.55 Million SEK | -183.035% |
| Biovica International AB (publ) | -124.82 Million SEK | 39.789% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -78.0% |
| Abliva AB (publ) | -95.5 Million SEK | 21.309% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 77.009% |
| 2cureX AB (publ) | -32.51 Million SEK | -131.124% |
| I-Tech AB | 20.2 Million SEK | 472.009% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 90.964% |
| Cyxone AB (publ) | -22.98 Million SEK | -226.926% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 17.772% |
| Biosergen AB | -27.03 Million SEK | -177.978% |
| SynAct Pharma AB | -215.81 Million SEK | 65.174% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -70.602% |
| BioInvent International AB (publ) | -330.3 Million SEK | 77.246% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -216.624% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 69.83% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -656.867% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 31.23% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -543.578% |